Tech Company Financing Transactions
ImmPACT Bio USA Funding Round
Bukwang Pharmaceutical, Hayan Health Networks and Johnson & Johnson Development Corporation participated in a $18 million Series A funding round for ImmPACT Bio USA. The financing round was announced on 8/21/2020.
Transaction Overview
Company Name
Announced On
8/21/2020
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4010 Adolfo Rd.
Camarillo, CA 93012
USA
Camarillo, CA 93012
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our technology addresses the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rick Kendall
VP - R & D
Frank Calzone
Browse more venture capital transactions:
Prev: 8/21/2020: Exo Imaging venture capital transaction
Next: 8/21/2020: Humaity App venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs